Drug prices and research and development investment behavior in the pharmaceutical industry

Journal of Law and Economics

Volumn 48, Issue 1, 2005, Pages 195-214

  Giaccotto, Carmelo ^a   Santerre, Rexford E ^a   Vernon, John A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 20744458237     PISSN: 00222186     EISSN: None     Source Type: Journal    
DOI: 10.1086/426882     Document Type: Article

References (32)

1. Baily, Martin Neil. "Research and Development Costs and Returns: The U.S. Pharmaceutical Industry." Journal of Political Economy 80 (1972): 70-85.
2. Berndt, Ernst R.; Griliches, Zvi; and Rosett, Joshua G. "Auditing the Producer Price Index: Micro Evidence from Prescription Pharmaceutical Preparations." Journal of Business and Economic Statistics 11 (1993): 251-64.
3. Congressional Budget Office. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. Washington, D.C.: Congressional Budget Office, 1998.
4. DiMasi, Joseph A. "Success Rates for New Drugs Entering Clinical Testing in the United States." Clinical Pharmacology and Therapeutics 58 (1995): 1-14.
5. DiMasi, Joseph A.; Hansen, Ronald W.; and Grabowski, Henry G. "Cost of Innovation in the Pharmaceutical Industry." Journal of Health Economics 10 (1991): 107-42.
6. DiMasi, Joseph A.; Hansen, Ronald W.; and Grabowski, Henry G. "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics 22 (2003): 151-85.
7. Ellison, Sara Fisher, and Mullin, Wallace P. "Gradual Incorporation of Information: Pharmaceutical Stocks and the Evolution of President Clinton's Health Care Reform." Journal of Law and Economics 44 (2001): 89-129.
8. Grabowski, Henry G. "The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries." Journal of Political Economy 76 (1968): 292-306.
9. Grabowski, Henry G. Health Reform and Pharmaceutical Innovation. Washington, D.C.: AEI Press, 1994.
10. Grabowski, Henry G., and Vernon, John M. "The Determinants of R&D Expenditures in the Pharmaceutical Industry." In Drugs and Health: Economic Issues and Policy Objectives, edited by Robert B. Helms, pp. 3-20. Washington, D.C.: America Enterprise Institute for Public Policy Research, 1981.
11. Grabowski, Henry G., and Vernon, John M. "Longer Patents for Lower Imitation Barriers: The 1984 Drug Act." American Economic Review: Papers and Proceedings 76 (1986): 195-98.
12. Grabowski, Henry G., and Vernon, John M. "A New Look at the Returns and Risks to Pharmaceutical R&D." Management Science 36 (1990): 804-21.
13. Grabowski, Henry G., and Vernon, John M. "Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Act." Journal of Law and Economics 35 (1992): 331-50.
14. Grabowski, Henry G., and Vernon, John M. "Returns to R&D on New Drug Introductions in the 1980s." Journal of Health Economics 13 (1994): 383-406.
15. Grabowski, Henry G., and Vernon, John M. "The Determinants of Pharmaceutical Research and Development Expenditures." Journal of Evolutionary Economics 10 (2000): 201-15.
16. Greene, William H. Econometric Analysis. 5th ed. Upper Saddle River, N.J.: Prentice Hall, 2003.
17. Hall, Bronwyn H. "Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?" Working Paper No. 4096. Cambridge, Mass.: National Bureau of Economic Research, 1992.
18. Hausman, Jerry. "Sources of Bias and Solutions to Bias in the Consumer Price Index." Journal of Economic Perspectives 17, No. 1 (2003): 23-44.
19. Hubbard, R. Glenn. "Capital-Market Imperfections and Investment." Journal of Economic Literature 36 (1998): 193-225.
20. Lichtenberg, Frank R. "Do (More and Better) Drugs Keep People Out of Hospitals?" American Economic Review: Papers and Proceedings 86 (1996): 384-88.
21. Lichtenberg, Frank R. "Are the Benefits of Newer Drugs Worth Their Cost? Evidence from the 1996 MEPS." Health Affairs 20, No. 5 (2001): 241-51.
22. Lichtenberg, Frank R. "Probing the Link between Gross Profitability and R&D Spending." Health Affairs 20, No. 5 (2001): 221-22.
23. Lichtenberg, Frank R. "The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001." Working Paper No. 9754. Cambridge, Mass.: National Bureau of Economic Research, 2003.
24. Organisation for Economic Co-operation and Development. OECD Health Data 2002: A Comparative Analysis of 30 Countries. Paris: OECD, 2002.
25. Pharmaceutical Manufacturers Association. Year Book 1970-1971. Washington, D.C.: Pharmaceutical Manufacturers Association, 1971.
26. Pharmaceutical Research and Manufacturers Association. 2003 Industry Profile. Washington, D.C.: PhRMA, 2003.
27. Scherer, F. M. "Pricing, Profits, and Technological Progress in the Pharmaceutical Industry." Journal of Economic Perspectives 7, No. 3 (1993): 97-115.
28. Scherer, F. M. Industry Structure, Strategy, and Public Policy. New York: Harper Collins College Publishers, 1996.
29. Scherer, F. M. "The Link between Gross Profitability and Pharmaceutical R&D Spending." Health Affairs 20, No. 5 (2001): 216-20.
30. Vernon, John A. "Drug Research and Price Controls." Regulation 25, No. 4 (2003): 22-26.
31. Vernon, John A. "Examining the Link between Price Regulation and Pharmaceutical R&D Investment." Health Economics 14 (2005): 1-16.
32. Weidenbaum, Murray. "Are Drug Prices Too High?" Public Interest, Summer 1993, pp. 84-89.